The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (BC): primary phase 1b results.
 
Javier Cortes
Employment - MedSIR
Stock and Other Ownership Interests - MedSIR
Honoraria - Celgene; Eisai; Novartis; Roche/Genentech
Consulting or Advisory Role - Celgene; Roche/Genentech
 
Noelia Martinez Janez
No Relationships to Disclose
 
Marie-Paule Sablin
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Jose Alejandro Perez-Fidalgo
Consulting or Advisory Role - Bayer; Ipsen; Teva
Speakers' Bureau - MSD; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Patrick Neven
No Relationships to Disclose
 
Elham Hedayati
Consulting or Advisory Role - Roche (Inst)
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Alexandra Ballester
Employment - Boehringer Ingelheim
 
Marie-Paule Ehrhart
No Relationships to Disclose
 
Dennis C Huang
Employment - Boehringer Ingelheim
 
Thomas Bogenrieder
Employment - Boehringer Ingelheim
 
Peter Schmid
Honoraria - AstraZeneca; Pfizer
Consulting or Advisory Role - Genentech (I)
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Genentech (Inst)